ASCO 2023
Stay up-to-date with the latest research and clinical updates from the 2023 ASCO Annual Meeting.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Updated PFS data was presented for the first phase 3, randomized trial to test the benefit of ICI rechallenge in mRCC.
Dr. Deek highlights his analysis of NRG RTOG 0524 and 0712 for prognostic significance of immune cell infiltration in MIBC.
Dr. Garje provides survival outcomes of sarcomatoid UC in patients with T2-T4, N0-N1 bladder cancer after definitive therapy.
Drs. Calais, Wallis discuss a post-hoc that showed PSMA PET as effective for treating pelvic, extrapelvic recurrent PC.
Dr. Voss highlights the research concerning IO-TKI combination, triplets, and other treatment approaches for RCC.
Drs. Armstrong and Wallis discuss the design of an AI-derived pathology-based biomarker for localized high-risk prostate.
CBM588 may improve clinical outcomes for patients with mRCC when combined with the cabozantinib plus nivolumab.
The combination treatment of dual-PSMA targeting with mAb and SML is feasible, and a follow-up study is in progress.
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Results of the STARTAR phase 2 trial on salvage RT plus apalutamide and docetaxel were presented at the 2023 ASCO meeting.
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
A post hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Questions from the surveys were rated as relevant or nonrelevant by patients with RCC.
Results outlined patient-reported outcomes from the TALAPRO-2 trial on first-line talazoparib plus enzalutamide for mCRPC.
A study from ASCO 2023 surveyed patients to determine how they prioritize their treatment selection for mRCC.
Researchers conducted an exploratory follow-up analysis of HRQoL in treament with nivolumab plus cabozantinib vs sunitinib.
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
EV plus pembrolizumab continues to demonstrate promising survival trends with durable responses in first-line la/mUC.
The prevalence, outcomes of patients with HRR mutations who initiated 1L mCRPC treatment with a novel hormonal therapy.
PSA nadir ≥0.1 ng/mL within 6 months of RT completion may be prognostic for long-term outcomes in patients receiving ...
A prospective study shows activity after treatment intensification with a triplet combination regimen in patients with RCCvh.
The largest analysis of outcomes for patients with sarcomatoid or rhabdoid metastatic nccRCC treated with IO-based regimens.
Post hoc analyses from JAVELN Bladder 100 shed light on the long-term safety profile of avelumab first-line maintenance.
Advertisement
Advertisement
